Navigation Links
Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Brothers' Movie to Be Filmed About Him

See Related Website at

FRESNO, Calif., March 25 /PRNewswire/ -- Cypress Systems, Inc., a Fresno, CA based biotechnology company, announced that it has promoted Mark E. Whitacre, Ph.D. to become the company's Chief Operating Officer (COO) and President of Operations. Dr. Whitacre joined the executive management team in December 2006 as President of Technology and Business Development for the new East Coast office. The company's CEO & President, Paul A. Willis, stated that, "By having Mark Whitacre as a part of the management team, we have taken a significant step in our effort to expand our selenium based cancer prevention research and to develop next generation products. Dr. Whitacre's research and top-management business experience has fully aligned with the future direction of the company and its continued expansion into fermentation technology with emphasis on biotechnology and life science applications. In the fifteen months since Dr. Whitacre joined the company, he has proven to be a valuable part of the management team."

*(PHOTO 72dpi:

*(Photo Caption: Mark Whitacre.)

In an effort to provide greater detail related to Dr. Whitacre's extensive education, research accomplishments, management experience, professional career, and his current work with Cypress, the company launched a biography website at last year. Dr. Whitacre's education includes B.S. and Master's degrees from Ohio State University and a Ph.D. in Nutritional Biochemistry from Cornell University where Mark's Ph.D. thesis adviser was a renowned selenium researcher, Dr. G.F. Combs, Jr. Dr. Whitacre's research at Cornell University related to the biochemical role of selenium at the cellular level in the prevention of diseases. Mark continued his studies after Cornell earning multiple advanced degrees, including a law degree. These and other accomplishments are listed on the biography website just provided.

The company's flagship branded ingredient, SelenoExcell(R) High Selenium Yeast, was standardized and approved as the research standard selenium yeast source by the Division of Cancer Prevention of the National Cancer Institute, which resulted in the signing of a Clinical Trial Agreement in 1998. As a result of these efforts, SelenoExcell(R) has been selected as the sole intervention agent in a series of cancer prevention and health related trials. See The company maintains a clear focus on the mission to advance the prevention of cancer [as opposed to treatment] through selenium supplementation and overall health stewardship.

Movie to be filmed starting April 2008: Dr. Mark Whitacre is best known publicly for his role as the whistleblower in the 1992 price fixing case involving the Archer Daniels Midland (ADM) Company. Mark was a former President of the ADM BioProducts Division and Corporate Vice President of the company. Warner Brothers will begin production in April 2008 of a feature film depicting the FBI undercover work by Mark Whitacre and detailing the ADM price fixing case. The movie and script will be based on the Kurt Eichenwald book published in 2000, "The Informant." The Steven Soderbergh directed movie has cast Matt Damon in the role of Mark Whitacre.

The ADM price fixing case is well documented in hundreds of articles and was the subject of two books. Besides "The Informant" by Kurt Eichenwald, James B. Lieber, an attorney, wrote a book titled, "Rats in the Grain." Lieber's detailed book, written as a documentary, portrayed Mark Whitacre as an American hero. In support of his own conclusions of his book, James Lieber has been very active along with Paul Willis and Dean Paisley (former FBI Supervisor of the ADM case) in a serious attempt to obtain Presidential Executive Clemency or a Pardon for Dr. Whitacre. Furthermore, the numerous supporters of Mark Whitacre are still very active today with this endeavor including Chuck Colson and Harmon Killebrew. In support of this effort, in early March 2008, Dean Paisley, a now retired 25-year veteran of the FBI, joined Mark Whitacre in Washington, D.C. where they jointly met with government lawyers. The objective of the meeting was to present strong support for Executive Clemency by all three FBI agents, including Brian Shepard who maintained day-to-day contact with Mark Whitacre during the case, and one of the former prosecutors who worked on the original case. Dean Paisley has said, "Such strong pardon support from several current and former Department of Justice officials is unprecedented."

Cypress President Paul Willis said, "We support Mark Whitacre 110%! Mark has proven to be a valued asset to our management team. Mark openly admits to his mistakes and wishes that things had turned out differently. We are fully aware of the details of this case and Mark's specific involvement. We consider ourselves to be among a growing list of supporters, which include the FBI agents just named among other agents, former U.S. and Canadian prosecutors involved with the case, several prominent law firms, and numerous other business professionals. We are strong believers in second chances and Mark most certainly has earned the right to a second chance. We at Cypress desire to move forward from this point and make a positive contribution regarding the importance of selenium from selenium yeast in cancer prevention and several other health-related research areas."

Mr. Willis added, "Let it be known, that we maintain high respect for the Archer Daniels Midland Company (ADM) and their current management team. We are fully aware that they have been under new management for several years and, like so many others who were involved in this case, wish only to put this behind them and move forward with the process of building a strong, vibrant and rewarding future for their companies and their personnel."

Cypress Systems, Inc. Website:

This release was issued on behalf of the above organization by Send2Press(R), a unit of Neotrope(R).

SOURCE Cypress Systems, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. USANAs CEO Myron W. Wentz, Ph.D. Has Been Elected to Serve on Immunosyn Corporations Board of Directors
2. febit Appoints Michelle Lyles, Ph.D., Vice President, Marketing and Sales
3. John E. Leonard, Ph.D., Former Biogen Idec Antibody Development Executive, Joins the Scientific Advisory Board of Vaccinex, Inc.
4. NeoStems Denis Rodgerson, Ph.D. to Lecture on Stem Cells and Regenerative Medicine at University of Nevada Las Vegas Campus
5. Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors
6. BiPar Names Hoyoung Huh, M.D., Ph.D. President and Chief Executive Officer
7. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
8. Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
9. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
10. Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors
11. Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
Post Your Comments:
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... Mass. , Nov. 25, 2015 Harvard ... biotechnology company developing bioengineered organ implants for life-threatening conditions, ... present at the LD Micro "Main Event" investor conference ... The presentation will be webcast live and posted for ... be available at the conference for one-on-one meetings on ...
(Date:11/25/2015)... Oregon , November 25, 2015 ... Market Research Report is a professional and in-depth ... industry.      (Logo: ) ... overview of the industry including definitions, classifications, applications ... is provided for the international markets including development ...
(Date:11/24/2015)... 2015 Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will ... New York on Wednesday, December 2 at 9:30 a.m. ... and CEO, will provide a corporate overview. th ... at 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola ... a corporate overview. --> th Annual Oppenheimer Healthcare ...
Breaking Biology Technology:
(Date:11/17/2015)... Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" and ... of broadly enabling, pressure cycling technology ("PCT")-based sample preparation ... it has received gross proceeds of $745,000 from an ... "Offering"), increasing the total amount raised to date in ... are expected in the near future. ...
(Date:11/12/2015)... , Nov. 12, 2015  Arxspan has entered ... MIT and Harvard for use of its ArxLab ... management tools. The partnership will support the institute,s ... and chemical research information internally and with external ... used for managing the Institute,s electronic laboratory notebook, ...
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
Breaking Biology News(10 mins):